

2022

Ciesielski TH, Zhang X, Tacconelli A, Lutsar I, de Cabre VM, Roilides E, Ciccacci C, Borgiani P, Scott WK; NeoMero Consortium, Williams SM, Sirugo G. Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway. *Pediatr Res* 2022 Jul 14. [Lien PubMed](#)

Chéret A, Bauer R, Meiffredy V, Lopez P, Ajana F, Lacombe K, Morlat P, Lascoux C, Reynes J, Calin R, Abel S, Goujard C, Rouzioux C, Avettand-Fenoel V, Meyer L. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. 2022 Jun 28 [Lien PubMed](#)

Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, Yom S, Vong C, Yin S, Ros B, Ky V, Pech S, Nem B, Hout K, Guillebaud J, Ear E, Caroupaye-Caroupin L, Rekacewicz C, Fernandez L, Laurent D, Yay C, Kim R, Meyer L, Chhun S, Borand L for the ANRS 12345 TA PROHM Study Group. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia: the ANRS 12345 TA-PROHM single-arm trial. *Lancet Inf Dis* 2022. [Lien PubMed](#)

Molino D, Durier C, Radenne A, Desaint C, Ropers J, Courcier S, Vieillard LV, Rekacewicz C, Parfait B, Appay V, Batteux F, Barillot E, Cogné M, Combadière B, Eberhardt CS, Gorochov G, Hupé P, Ninove L, Paul S, Pellegrin I, van der Werf S, Lefebvre M, Botelho-Nevers E, Ortega-Perez I, Jaspard M, Sow S, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Launay O. A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project. *Nat Med.* 2022 May 5 [Lien PubMed](#)

Luong Nguyen LB, Bauer R, Lesieur Z, Galtier F, Duval X, Vanhems P, Lainé F, Tattevin P, Durier C, Launay O. FLUVAC Study group. Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study. *Infect Dis Now.* 2022 Feb [Lien PubMed](#)

Mariaggi A-A, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, Lacombe K, Pialoux G, Cua E, Rouzioux C, Meyer L, Chéret A; Avettand-Fenoel V. HIV-1 RNA and total HIV-1 DNA loads in genital compartment in men receiving Dolutegravir- versus Darunavir-based cART regimens during the primary HIV infection. *Journal of Antimicrobial Chemotherapy.* 2022 Feb 23 [Lien PubMed](#)

Zeggagh J, Bauer R, Delaugerre C, Carette D, Fressard L, Charreau I, Chidiac C, Pialoux G, Tremblay C, Cua E, Robineau O, Raffi F, Capitant C, Spire B, Meyer L, Molina JM and the Ipergay study group. Incidence and risk factors for recurrent sexually transmitted infections among men who have sex with men on HIV pre-exposure prophylaxis. *AIDS* 2022 Feb 9 [Lien PubMed](#)

Durier C, Mercier-Delarue S, Verdière NC, Meiffredy V, Matheron S, Samri A, Resch M, Marchand L, Autran B, Launay O, Simon F; ANRS NOVAA EP46 study group. A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults. *AIDS.* 2022 Feb 1. [Lien PubMed](#)

Launay O, Artaud C, Lachâtre M, Ait-Ahmed M, Klein J, Luong Nguyen LB, Durier C, Jansen B, Tomberger Y, Jolly N, Grossmann A, Tabbal H, Brunet J, Gransagne M, Choucha Z, Batalie D, Delgado A, Müllner M, Tschismarov R, Berghmans PJ, Martin A, Ramsauer K, Escriou N, Gerke C. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. *EBioMedicine.* 2022 Jan 16 [Lien PubMed](#)

2021

Turkova A, White E, A. Mujuru H, R. Kekitiinwa A, M. Kityo C, Violari A, Lugemwa A, R. Cressey T, Musoke P, Variava E, F. Cotton M, Archary M, Puthanakit T, Behuhuma O, Kobbe R, B. Welch S, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, M. Ahimbisibwe G, Chalermpanmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, M. Gibb D for the ODYSSEY Trial Team. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. *N Engl J Med.* 2021 Dec 30. [Lien PubMed](#)

Gras J, Pillet M, Antoni G, Cua E, Charreau I, Raffi F, Chidiac C, Chas J, Tremblay C, Pasquet A, Spire B, Delaugerre C, Meyer L, Molina JM. Risk Factors for HIV Infection Among Men who have sex with men in the ANRS IPERGAY PrEP Trial. *Sex Transm Inf.* 2021 Oct 18 [Lien PubMed](#)

Berçot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, Capitant C, Bourgeois-Nicolaos N, Raffi F, Pereyre S, Le Roy C, Senneville E, Meyer L, Bébéar C, Molina JM. High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial. *Clin Infect Dis.* 2021 Oct 5. [Lien PubMed](#)

Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialoux G, Cua E, Laghzal A, Bushman L, Anderson P, Mourah S, Meyer L, Molina JM. Estimated pill intake with on demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blot spots in the ANRS IPERGAY trial. *Journal of Antimicrobial Chemotherapy.* 2021 Sept 15 [Lien PubMed](#)

Chas j, Bauer B, Larabi IA, Peytavin G, Roux P, Cua E, Cotte L, Pasquet A, Capitant C, Meyer L, Raffi F, Spire B, Pialoux G, Molina JM, Alvarez JC. Evaluation of Drug Abuse by Hair Analysis and Self-Reported Use Among MSM Under PrEP: Results From a French Substudy of the ANRS-IPERGAY Trial. *J Acquir Immune Defic Syndr.* 2021 Apr 15. [Lien PubMed](#)

Chawki S, Charreau I, Gabassi A, Carette D, Cua E, Cotte L, Pialoux G; Pintado C, Meyer L, Delaugerre C, Molina JM. Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). *Open Forum Infect Dis.* 2021 Mar 20. [Lien PubMed](#)

Nguyen T, Valantin MA, Delaugerre C, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. *J Glob Antimicrob Resist* 2021 Mar 24. [Lien PubMed](#)

Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saïdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. *BMC Infect Dis.* 2021 Jan 4. [Lien PubMed](#)

2020

Novelli S, Lécuroux C, Goujard C, Reynes J, Villemant A, Blum L, Essat A, Avettand-Fenoël V, Launay O, Molina JM, Bourgeois C, Meyer L. Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection. *EBioMedicine.* 2020 Nov 25. [Lien PubMed](#)

Bauer R, Netzer E, Pintado C, Capitant C, Cua E, Etien N, Fonsart J, Pialoux G, Chidiac C, Etienne C, Doré V, Meyer L, Molina JM. Coverage of sex acts by event-driven pre-exposure prophylaxis – A sub-study of the ANRS IPERGAY Trial"; *AIDS Behav.* 2020 Nov 24. [Lien PubMed](#)

Di Ciaccio M, Sagaon-Teyssier L, Mimi M, Suzan-Monti M, Protière C, Rojas Castro D, Meyer L, Tremblay C, Chidiac C, Capitant C, Préau M, Molina JM, Spire B. Changes in sexual behaviors in men who have sex with men: a comparison between the double-blind and open-label extension phases of the ANRS-IPERGAY trial; *AIDS Behav.* 2020 Nov 24. [Lien PubMed](#)

Freguja R, Bamford A, Zanchetta M, Del Bianco P, Giaquinto C, Harper L, Dalzini A, Cressey TR, Compagnucci A, Saïdi Y, Riault Y, Ford D, Gibb D, Klein N, De Rossi A; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children. *HIV Med.* 2020 Oct 29. [Lien PubMed](#)

Pauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, Shafic Makumbi, Adeodata R Kekitiinwa, Elisabeth Kaudha, Anna Parker, Godfrey Musoro, Annet Nanduudu, Abbas Lugemwa, Pauline Amuge, James G Hakim, Pablo Rojo, Carlo Giaquinto, Angela Colbers, Diana M Gibb, Deborah Ford, Anna Turkova, David M Burger, and the ODYSSEY trial team. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. *Lancet HIV.* 2020 Aug. [Lien PubMed](#)

Di Ciaccio M, Fressard L, Sagaon-Teyssier L, Protiere C, Gatey C, Chas J, Cotte L, Castro DR, Meyer L, Molina JM, Préau M, Spire B. What are the situational and behavioral factors associated with condomless anal sex without PrEP in men who have sex with men? Results from the ANRS-IPERGAY trial. AIDS. 2020 Apr 13 [Lien PubMed](#)

Segeral O, Dim B, Durier C, Prak S, Chhim K, Vong C, Pech S, Tiv S, Nem B, Hout K, Nouhin J, Chhun S, Borand L. HBeAg rapid test and alanine aminotransferase level-based algorithm to identify pregnant women at risk of HBV mother-to-child transmission: the ANRS 12345 TA PROHM study. Clin Infect Dis. 2020 Mar 19 [Lien PubMed](#)

Lutsar I, Chazallon C, Trafojer U, Meiffredy de Cabre V, Auriti C, Bertaina C, Calo Carducci FI, Canpolat FE, Esposito S, Fournier I, Hallik M, Metsvaht T, Mitsiakos G, Pana ZD, Mosca F, Pagni L, Roilides E, Rossi P, Srafidis K, Sanchez L, Sharland M, Usonis V, Warris A, Aboulker JP, Giaquinto C and on behalf of NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. PLOS ONE 2020 Mar 4 [Lien PubMed](#)

Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, Tremblay C, Cua E, Senneville E, Raffi F, Meyer L, Molina JM, ANRS-IPERGAY study group. Changes in Kidney Function Among High Risk Gay Men Initiating on Demand Tenofovir Disoproxil Fumarate - Emtricitabine in Prophylaxis of HIV Infection in the ANRS IPERGAY Study. JIAS. 2020 Feb 23. [Lien PubMed](#)

Cotte L, Veyer D, Charreau I, Péré H, Cua E, Carette D, Chas J, Capitant C, Chidiac C, Fléjou JF, Fouéré S, Heard I, Meyer L, Puech J, Tremblay C, Delaugerre C, Molina JM. Prevalence and incidence of HPV infection in men having sex with men enrolled in a PrEP study: A sub-study of the ANRS IPERGAY trial. Clin Inf Dis. 2020 Jan 7. [Lien PubMed](#)

Gras J, Mahjoub N, Charreau I, Cotte L, Tremblay C, Chas J, Raffi F, Cua E, Guillon B, Guigue N, Chaix ML, Meyer L, Molina JM, Delaugerre C; and the Ipergay study group. Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis. AIDS. 2020 Jan 1. [Lien PubMed](#)

2019

Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina J-M and the ANRS IPERGAY study group. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV 2019 Nov 26. [Lien PubMed](#)

Durier C, Desaint C, Lelièvre JD, Silbermann B, Pialoux G, Cuzin L, Bonnet B, Poizot-Martin I, Bouakane A, Paul C, Grabar S, Spire B, Meyer L, Launay O; ANRS/VRI COHVAC Study Group. Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials. AIDS. 2019 Nov 1. [Lien PubMed](#)

Di Ciaccio M, Sagaon-Teyssier L, Protiere C, Mimi M, Suzan M, Meyer L, Rojas Castro D, Pialoux G, Pintado C, Spire B. Impact of HIV risk perception on both PrEP and condom use. Journal of Health Psychology 2019 Oct 24. [Lien PubMed](#)

Puppo C, Mabire X, Morel S, Laguette V, Rojas Castro D, Chas J, Cua E, Pintado C, Suzan-Monti M, Spire B, Molina JM, Preau M. Becoming adherent to a preventive treatment for HIV: a qualitative approach. Psychology, Health and Medicine. 2019 Jul 11. [Lien PubMed](#)

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, L'yavanc T, Ohayon M, Israel G, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. Int J Antimicrob Agents. 2019 Jun 10. [Lien PubMed](#)

Puppo C, Mabire X, Cotte L, Castro DR, Spire B, Cua E, Pialoux G, Monti MS, Pasquet A, Raffi F, Molina JM, Préau M; ANRS-Ipergay Study Group. Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention. AIDS Educ Prev. 2019 Jun 3. [Lien PubMed](#)

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, L'yavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Shared HCV Transmission Networks among HIV-1-Positive and HIV-1-Negative Men Having Sex with Men by Ultradeep Sequencing. *J Acquir Immune Defic Syndr*. 2019 May 21. [Lien PubMed](#)

Chaillon A, Delaugerre C, Brenner B, Armero A, Capitant C, Nere ML, Leturque N, Pialoux G, Cua E, Tremblay C, Smith DM, Goujard C, Meyer L, Molina JM, and Chaix ML. In Depth Sampling of High Risk Populations to Characterize HIV Transmission Epidemics among Young MSM using PrEP in France and Quebec. *Open Forum Infectious Diseases*. 2019 Feb 6 [Lien PubMed](#)

2018

Chaix ML, Charreau I, Pintado C, Delaugerre C, Mahjoub N, Cotte L, Capitant C, Raffi F, Cua E, Pialoux G, Tremblay C, Meyer L, Molina JM and the ANRS IPERGAY study group. Effect of On Demand Oral Preexposure prophylaxis with Tenofovir/Emtricitabine on HSV-1/2 Incidence among Men who have sex with Men: a sub-study of the ANRS IPERGAY trial. *Open Forum Infectious Diseases*. 2018 Nov 08 [Lien PubMed](#)

Rodriguez C, Nere ML, Demontant V, Charreau I, Mercier-Darty M, Delagreverie H, Salmona M, de Castro N, Chaix ML, Molina JM, Delaugerre C. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia. *J Antimicrob Chemother*. 2018 Nov 1 [Lien PubMed](#)

Delaugerre C, Rodriguez C, Capitant C, Nere ML, Mercier-Darty M, Carette D, Pialoux G, Cotte L, Charreau I, Molina JM and the IPERGAY study group. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. *AIDS* 2018 Oct 23 [Lien PubMed](#)

Sagaon-Teyssier L, Mabire X, Laguette V, Fressard L, Suzan-Monti M, Rojas-Castro D, Hall N, Capitant C, Meyer L, Chidiac C, Tremblay C, Preau M, Spire B, Molina JM. A Group-based Trajectory Model for Changes in Pre-exposure Prophylaxis (PrEP) and Condom Use Among Men Who Have Sex with Men Participating in the ANRS IPERGAY Trial. *AIDS Patient Care and STDs* 2018 [Lien](#)

Trachman M, Girard G. Targeting Fallible Men: Communication Strategies and Moral Issues in a Pre-exposure Prophylaxis Trial. *J Acquir Immune Defic Syndr*. 2018 Oct 1. [Lien PubMed](#)

Roux P, Fressard L, Suzan-Monti M, Chas J, Sagaon-Teyssier L, Capitant C, Meyer L, Tremblay C, Rojas-Castro D, Pialoux G, Molina JM, Spire B. Is on-Demand HIV Pre-exposure Prophylaxis a Suitable Tool for Men Who Have Sex With Men Who Practice Chemsex? Results From a Substudy of the ANRS-IPERGAY Trial. *J Acquir Immune Defic Syndr*. 2018 Oct 1. [Lien PubMed](#)

Durier C, Desaint C, Launay O. Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC Cohort. *J Acquir Immune Defic Syndr*. 2018 Oct 1. [Lien PubMed](#)

Colin De Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; and the ANRS EP46 NOVAA Group. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients: ANRS EP46 NOVAA. *AIDS* 2018 Aug 8. [Lien PubMed](#)

Chéret A, Durier C, Noël N, Bourdic K, Legrand C, D'Andréa C, Hem E, Goujard C, Berthiaume P, Consoli SM. Motivational interviewing training for medical students: A pilot pre-post feasibility study. *Patient Educ Couns*. 2018 Jun 21. [Lien PubMed](#)

Di Ciaccio M, Protiere C, Rojas Castro D, Suzan-Monti M, Chas J, Cotte L, Siguiet M, Cua E, Spire B, Molina JM, Preau M; ANRS IPERGAY Study Group. The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship. *AIDS Care* 2018 Jun 30. [Lien PubMed](#)

Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpanmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. *PLoS One*. 2018 Apr 23. [Lien PubMed](#)

Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF1,4; NeoMero Consortium. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. *J Antimicrob Chemother.* 2018 Apr 19. [Lien PubMed](#)

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Le Mestre S, Doré V, and Meyer L, for the ANRS IPERGAY Study Group. Post-Exposure Prophylaxis with Doxycycline to Prevent Sexually Transmitted Infections in Men Who Have Sex with Men: A Randomised Open-Label Study. *Lancet ID.* 2018 Mar 18 [Lien PubMed](#)

Durand-Zaleski I, Mutuon P, Charreau I, Tremblay C, Rojas D, Pialoux G, Chidiac C, Capitant C, Spire B, Cotte L, Chas J, Meyer L, Molina JM for the ANRS IPERGAY Study Group. Costs and benefits of On-Demand HIV Preexposure Prophylaxis in MSM. *AIDS* 2018. Jan 2. [Lien PubMed](#)

Suzan-Monti M, Cotte L, Fressard L, Cua E, Capitant C, Meyer L, Pialoux G, Molina JM, Spire B. Factors associated to Partner notification of sexually transmitted infections in men who have sex with men on PrEP in France: a cross-sectional sub-study of the ANRS IPERGAY trial. *Sexually Transmitted Infections.* 2018 Jan 2. [Lien PubMed](#)

2017

Sirima S.B, C. Durier, L. Kara, S. Houard, A. Gansane, P. Loulergue, M. Bahuaud, N. Benhamouda, I. Nebié, B. Faber, E. Remarque, O. Launay. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. *Vaccine.* 2017 Sept 22 [Lien PubMed](#)

Melvin AJ, Warshaw M, Compagnucci A, Saidi Y, Harrison L, Turkova A, Tudor-Williams G; PENPACT-1 (PENTA 9/PACTG 390/ANRS 103). Study Team. Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy. *J Pediatric Infect Dis Soc.* 2017 Sep 1. [Lien PubMed](#)

Delaugerre C, Antoni G, Mahjoub N, Pialoux G, Cua E, Pasquet A, Hall N, Tremblay C, Cotte L, Capitant C, Chaix ML, Meyer L, Molina JM; IPERGAY Study Group. Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs. *J Infect Dis.* 2017 Aug 1. [Lien PubMed](#)

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Le Mestre S, Chidiac C, Pialoux G, Ponscarne D, Fonsart J, Thompson D, Wainberg M, Doré V, Meyer L for the ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. *Lancet HIV.* 2017 Jul 21 [Lien PubMed](#)

Chéret A, Durier C, Mélard A, Ploquin M, Heitzmann J, Lécuroux C, Avettand-Fenoël V, David L, Pialoux G, Chennebault JM, Müller-Trutwin M, Goujard C, Rouzioux C, Meyer L; ANRS OPTIPRIM study group. Impact of early cART on HIV blood and semen compartments at the time of primary infection. *PLoS One.* 2017 Jul 14 [Lien PubMed](#)

Mercier-Delarue S, Durier C, Colin de Verdière N, Poveda JD, Meiffredy V, Fernandez Garcia MD, Lastère S, Césaire R, Manuggera JC, Molina JM, Amara A, Simon F. Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype. *PLoS One.* 2017 May 31 [Lien PubMed](#)

2016

Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord. Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. *Euro Surveill* 2016;21(10) [Lien PubMed](#)

Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM. Uptake Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. *J Antimicrob Chemother.* 2016 Sep 28 [Lien PubMed](#)

BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. *Lancet HIV*. 2016 Sep 3 [Lien PubMed](#)

Barrail-Tran, Vincent C, Furlan V, Rosa I, Rosenthal E, Cheret A, Molina JM, Taburet AKheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfecting patients treated with boceprevir or telaprevir-based therapy. *AIDS*. 2016 Aug 24 [Lien PubMed](#)

Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfecting patients treated with boceprevir or telaprevir-based therapy. *AIDS* 2016 Aug 23 [Lien PubMed](#)

Marcellin F, Fournier I, Carrieri MP, Poizot-Martin I, Cotte L; and the ANRS HC26 & ANRSHC27 Study Groups. From first-generation HCV protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials); *Eur J Gastroenterol Hepatol*. 2016 Jun [Lien PubMed](#)

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption. *AIDS* 2016 Apr 24 [Lien PubMed](#)

De Castro N, Braun J, Charreau I, Lafeuillade A, Viard JP, Allavena C, Aboulker JP, Molina JM and The EASIER ANRS 138 study group. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. *AIDS Res Ther*. 2016 Apr 2 [Lien PubMed](#)

Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac, Chas, Meyer, Molina JM, Spire B; ANRS IPERGAY Study Group. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. *AIDS Care*. 2016 Feb 17 [Lien PubMed](#)

2015

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozemaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. *N Engl J Med* 2015 Dec 1. [Lien PubMed](#)

Harrison L., Melvin A., Fiscus S., Saidi Y., Nastouli E., Harper L., Compagnucci A., Babiker A., McKinney R., Gibb D., Tudor-Williams G. HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds. *JAIDS* 2015 Sept 1. [Lien PubMed](#)

Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. *Clin Infect Dis*. 2015 Sep 1. [Lien PubMed](#)

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med*. 2015 Aug 27. [Lien PubMed](#)

Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. *J Antimicrob Chemother*. 2015 Feb. [Lien PubMed](#)

Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevalier S, Aboulker JP, Taburet AM, Molina JM; ANRC HC; study Group. Telaprevir enhances ribavirin-induced anaemia through renal function impairment. *Antivir Ther.* 2015 Jan 6. [Lien PubMed](#)

2014

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miaillhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher G; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group. Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study. *Clin Infect Dis.* 2014 Oct 15;59(8):1177-84. doi: 10.1093/cid/ciu515. Epub 2014 Jul 3. [Lien PubMed](#)

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevalier S, Aboulker JP, Molina JM; for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 Telaprevir): An Open-Label, Single-Arm, Phase 2 Trial. *Clin Infect Dis.* 2014 Aug 18. [Lien PubMed](#)

Desaint C, Durier C, Poda A, Krivine A, Simon F, Bodilis H, Pialoux G, Cuzin L, Poizot-Martin I, Morineau P I, Lelievre JD, Silbermann B, Aoulker JP, Launay O for the ANRS COHVAC Cohort and the Vaccine Research Institute (VRI). Long-term persistence of vaccine-induced HIV seropositivity in healthy volunteers. *JAIDS Clin Res* 2014, 5:2 [Lien](#)

Diane E.T. Bastiaans, Silvia Forcat, Hermione Lyall, Tim R. Cressey, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Antoni Noguera-Julian, Christoph Königs, Jamie R.J. Inshaw, Suwalai Chalermpanmetagul, Yacine Saïdi, Alexandra Compagnucci, Lynda M. Harper, Carlo Giaquinto, Angela P.H. Colbers, and David M. Burger. Pharmacokinetics of paediatric lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. *The Pediatric Infections Disease Journal*, March 2014, 33 (3) [Lien PubMed](#)

Fontaine H, Kahi S, Chazallon C, Bourguine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S; for the ANRS HB02 study group. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. *Gut.* 2014 Feb 20. doi: 10.1136/gutjnl-2013-305707 [Lien PubMed](#)

Lutsar I, Chazallon C, Carducci FI, Trafojer U, Abdelkader B, Meiffredy V, Esposito S, Giaquinto C, Heath PT, Ilmoja ML, Katragkou A, Lascoux C, Metsvaht T, Mitsiakos G, Netzer E, Pugni L, Roilides E, Saïdi Y, Sarafidis K, Sharland M, Usonis V, Aboulker JP; NeoMero Consortium. Current management of late onset neonatal bacterial sepsis in five European countries. *Eur J Pediatr.* 2014 Feb 13 [Lien PubMed](#)

2013

De Lastours V, LeGoff J, Brière J, Agbalika F, Boulet T, Lévy Y, Simon F, Aboulker J-P and Molina J-M. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial. *HIV Médecine* (2013) [Lien PubMed](#)

Launay O, Surenaud M, Desaint C, Ben Hamouda N, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales G, Cuzin L, Bourgault-Villada I, Lévy Y, Choppin J, Durier C. Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). *Vaccine* 2013 Jul 11. j.vaccine.2013.06.102. [Lien PubMed®](#)

Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM and the ANRS 138 Easier study group. Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy. *J Infect Dis* 2013, 208 : 892-897. [Lien PubMed®](#)

Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelièvre JD, Chêne G, Thiébaud R, Lévy Y; ANRS Vaccine Network/Vaccine Research Institute. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. *AIDS*. 2013 Jun 1;27(9):1421-31. [Lien PubMed®](#)

Richert L, Thiebaut R; Biostatistics Bioinformatics Division of the ANRS Vaccine Research Institute. Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints? *AIDS*. 2013 May 15;27(8):1362-5. Collaborators: Richert L, Durier C, Surenaud M, Targat B, Wiedemann A, Hue S, Hocini H, Lacabaratz C, Legrand R, Thiébaud R.

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. *AIDS*. 2013 Feb 20;27(4):579-89. [Lien PubMed®](#)

Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; for the ANRS 151 study group and the REIVAC network. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults *AIDS*. 2013 Jan 2;27(1):87-93. [Lien PubMed®](#)

Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemand M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children: *AIDS Behav*. 2013 Jan;17(1):193-202. [Lien PubMed®](#)

2012

Le Corre N, Thibault F, Pouteil Noble C, Meiffredy V, Daoud S, Cahen R, Charreau I, Bottiglioli D, Dollinger C, Aboulker J-P, Autran B, Morelon E, Barrou B. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. *Vaccine* 2012 Oct 25. [Lien PubMed®](#)

Delaugerre C, Braun J, Charreau I, Delarue S, Nere M, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP ; the ANRS 138-EASIER study group. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. *HIV Med*. 2012 Oct;13(9):517-525. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14 [Lien PubMed®](#)

Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall JM, Cook E, Aboulker JP, Capitant C, Molina JM, Spire B. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. *AIDS Care*. 2012;24(4):468-77. [Lien PubMed®](#)

2011

Trancart S, Charreau I, Marchou M, Bocquentin M, Molina JM, Izopet J, Tangre P, Aboulker JP, Taburet AM, and ANRS 106 study group. Presence of Lamivudine or Emtricitabine is associated with reduced emergence of Nonnucleoside Reverse Transcriptase Inhibitor mutations in an Efavirenz-based intermittent antiretroviral treatment. *Antimicrob Agents Chemother* 2012, 56(3):1655 [Lien PubMed®](#)

Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS, the PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial *Original Text*. *The Lancet Infect Dis* 2011, 11:273-83. [Lien PubMed®](#)

Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, and Aboulker JP, for the ANRS 151 Hifluvac study group and the french clinical vaccinology network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine

adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. *J Infect Dis* 2011, 204:124-34. [Lien PubMed®](#)

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, De Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, and Molina JM on behalf of the EASIER ANRS 138 study group. Efficacy and Safety of Raltegravir in Treatment-Experienced HIV-1 Infected Patients Switching from Enfuvirtide-Based Regimens: 48-Week Results of the Randomized Easier - ANRS 138 Trial. *J Antimicrob Chemother* 2011, 66:2099-2106. [Lien PubMed®](#)

Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM* and Molina JM. Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a pharmacokinetic sub-study of the EASIER-ANRS 138 trial. *Antimicrob Agents and Chemotherapy* 2011, 55:3613-3615. [Lien PubMed®](#)

Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM and Kuritzkes DR. Emerging Integrase Inhibitor Resistance Mutations in Raltegravir-Treated HIV-1-Infected Patients with Low-Level Viremia. *AIDS* 2011, 25:665-9. [Lien PubMed®](#)

Tsatsaris V, Capitant C, Schmitz T, Chazallon C, Bulifon S, Riethmuller D, Picone O, Poulain P, Lewin F, Lainé F, Jacqz-Aigrain E, Aboulker JP, Launay O, for the Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine. *Ann Intern Med* 2011, 155:733-741. [Lien PubMed®](#)

Feeney ER*, Chazallon C*, O'Brien N, Meiffredy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PWG, on behalf of the INITIO Trial International Co-ordinating Committee. Hyperlactatemia in HIV-infected subjects initiating antiretroviral therapy in a large randomised study (a substudy of the INITIO trial). *HIV Medicine* Nov 2011, 12: 602-609. (* These authors equally contributed to this work) [Lien PubMed](#)

Lutsar I, Trafojer UM, Heath PT, Metsvaht T, Standing J, Esposito S, de Cabre VM, Oeser C, Aboulker JP; NeoMero Consortium. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. *Trials*. 2011 Sep 30;12:215. [Lien PubMed](#)

Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D; ANRS 127 study group. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. *AIDS*. 2011 Nov 13;25(17):2143-8. [Lien PubMed](#)

Gozaló C, Gérard L, Loiseau P, Morand-Joubert L, Peytavin G, Molina JM, Dellamonica P, Becquemont L, Aboulker JP, Launay O, Verstuyft C; ANRS 081 Study Group. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. *Basic Clin Pharmacol Toxicol*. 2011 Dec;109(6):513-20. doi: 10.1111/j.1742-7843.2011.00780.x. Epub 2011 Sep 6. [Lien PubMed](#)

Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker JP, Taburet AM, Molina JM, Massip P, Marchou B, Izopet J; ANRS 106-Window Study Team. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. *PLoS One*. 2011;6(6):e21655. Epub 2011 Jun 27. [Lien PubMed](#)

2010

Boulet T, Pavié J, Charreau I, Braun J, Reynes J, Morlat P, Piroth L, Spire B, Molina JM, Aboulker JP and the EASIER ANRS 138 study group. Impact on Health-related Quality of life of a switch from Enfuvirtide to Raltegravir among Multidrug-Resistant HIV-1 Infected Patients: A Randomized Open-Label Trial (Easier - ANRS 138). *HIV Clin Trials* 2010;11(5):283-293. [Lien PubMed](#)

Gibb DM, Castro H, Compagnucci A, Klein N, Lallemand M, Lyall H, Nadal D, Ananworanich J, Babiker A, Bunupuradah T, Darbyshire JH, De Rossi A, Gonzalez MI Tome, Harper L, Kanjavanit S, Marczyńska M, Mofenson L, Monpoux F, Moya J, Munoz-Fernandez MA, Ngo-Giang-Huong N, Niehues T, Saidi Y, Walker AS, U. Wintergerst U and Giaquinto C. Response to planned treatment interruptions in HIV infection varies across childhood. *AIDS*. 2010 Jan 16;24(2):231-41. [Lien PubMed](#)

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, and Taburet AM. Influence of Alpha-1 glycoprotein acid concentrations and variants on Atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 Trial. *Antimicrobial Agents and Chemother* 2010, 54:614-619. [Lien PubMed](#)

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaud R and NEAT-WP4. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. *Clin Trials* 2010, 7:19-35. [Lien PubMed](#)

Barau C, Delaugerre C, Braun J, De Castro N, Furlan V, Charreau I, Gérard L, Lascoux-Combe C, Molina JM, Taburet AM. High Concentration of Raltegravir in Semen of HIV-infected Men: a sub-study of the EASIER-ANRS 138 trial. *Antimicrob. Agents Chemother* 2010, 54(2):937-9. [Lien PubMed](#)

Durier C*, Salmon-Céron D*, Desaint C, Cuzin L, Surenaud M, Ben Hamouda N, Lelièvre J-D, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker J-P, Lévy Y, Launay O, for the ANRS VAC18 trial group. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. *AIDS*.2010 Sep 10;24. [Lien PubMed](#)

Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vézinet F, and Descamps D on behalf of the ANRS 127 Study Group. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients. *Antimicrob Agents Chemother* 2010, 54 (7):2910-19. [Lien PubMed](#)

Jacqz-Aigrain E, Harrison L, Zhao W, Compagnucci A, Castro H (née Green), Farrelly L, Saïdi Y, Hamadache D, Welch S, Wintergerst U, Forcat S, Hadjou G, Firtion G, Snowden W, Giaquinto C, Gibb D and Burger D, for the Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 2-36 months. *Antiviral Ther* 2010, 15:297-305. [Lien PubMed](#)

Fontas E, Kousignian I, Pradier C, Isabelle Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D, on behalf of FHDH ANRS CO4. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy-results from the ANRS CO4 cohort, ANRS CO14. *JAntimicrob Chemother* 2010, 65(10):2215-23. Epub 2010 Aug. 11. [Lien PubMed](#)

Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Ben Hamouda N, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O, for the ANRS VAC18 trial group. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. *AIDS* 2010, 24:2211-23. [Lien PubMed](#)

Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F, the ANRS 138 study group. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. *AIDS* 2010, 24:2391-95. [Lien PubMed](#)

2009

Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 ANRS CO14. Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients; results from FHDH ANRS CO4. *J Acquir Immune Defic Syndr* 2009, 50(2):206-14. [Lien PubMed](#)

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, and Yéni P, on behalf of the ANRS 127 study group. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naïve HIV-1-infected patients: the 2IP ANRS 127 study. *J Antimicrob Chemother* 2009, 64:118-125. [Lien PubMed](#)

Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM and the ANRS 106 study group. Incidence and Risk Factors of Thrombocytopenia in Patients Receiving Intermittent Antiretroviral Therapy: A Sub-study of the ANRS 106 - Window Trial. *JAIDS* 2009. [Lien PubMed](#)

Ceci A, Giaquinto C, Aboulker JP, Baiardi P, Bonifazi F, Della Pasqua O, Nicolosi A, Taruscio D, Sturkenboom M, Wong I. The Task-force in Europe for Drug Development for the Young (TEDDY) network of excellence. *Pediatr Drugs* 2009, 11:18-21. [Lien PubMed](#)

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). *J Infect Dis.* 2009, 200:206-15. [Lien PubMed](#)

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, and the EASIER ANRS 138 study group. Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial. *Clin Infect Dis.* 2009, 49:1259-67. [Lien PubMed](#)

Altavilla A, Giaquinto C, Giocanti D, Manfredi C, Aboulker JP, Bartoloni F, Cattani E, Lo Giudice M, Mellado Peña, Nagler R, Peterson C, Vajnerova O, Bonifazi F and Ceci A. Activity of ethics committees in Europe on issues related to clinical trials in paediatrics: results of a survey. *Pharmaceuticals Policy and Law* 2009, 11:79-87.

Larrouy L, Chazallon C, Landman R, Capitant C, Collin, G Storto A, Peytavin G, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D. Impact of Gag genetic determinants and gag-pol frameshift stability on virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive patients (ANRS 127 trial). *Antiviral Ther* 2009, 14:A61. [Lien PubMed](#)

Insight-Esprit Study Group, Silcaat Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. *N Engl J Med* 2009, 361:1548-59. [Lien PubMed](#)

Descamps D, Chazallon C, Loveday C, et al. Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial. *HIV Clin Trials* 2009, 10:385-393. [Lien PubMed](#)

2008

Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saïdi Y, Lallemand M, Gibb DM, and Burger DM, for the Paediatric European Network for Treatment of AIDS II Study Group. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. *Clin Infect Dis* 2008, 46:1601-08. [Lien PubMed](#)

Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP. HIV-1 resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4(+) T-cell counts and antiviral response. *Antiviral Therapy* 2008, 13(4):537-45. [Lien PubMed](#)

Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Paller C, Delfraissy JF, Lambotte O. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS* 2008, 22(10):1125-29. [Lien PubMed](#)

Charreau I, Jeanblanc G, Tangre P, Boyer L, Saouzanet M, Marchou B, Aboulker JP, Molina JM, Durand-Zaleski I and ANRS 106 study group. Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection. A substudy of the ANRS 106 Window trial. *J Acquir Immune Defic Syndr* 2008, 49(4):416-21. [Lien PubMed](#)

2007

Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM; ANRS 106 study team. Intermittent antiretroviral therapy in patients with controlled HIV infection. *AIDS.* 2007, 21:457-66. [Lien PubMed](#)

Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, Castelli-Gattinara G, Compagnucci A, Della Negra M, de Rossi A, Feiterna-Sperling C, Giaquinto C, Harper L, Levy J, Saïdi Y, Wintergerst U (Penta 5 trial). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS* 2007, 21:947-955. [Lien PubMed](#)

Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, Viard JP, Weiss L, Netzer E, Delfraissy JF, Aboulker JP, and Lévy Y. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). *AIDS* 2007, 21:1887-97. [Lien PubMed](#)

Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figueredo S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG, for the ANRS VAC16 Study Group. Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial. *PLoS One* 2007, 2(8):e725. [Lien PubMed](#)

Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Rouzioux C, Taoufik Y, El Habib R, Beumont-Mauviel M, Aboulker JP, Lévy Y, and Delfraissy JF for the PRIMOVAC-ANRS 095 Study Group. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. *AIDS Res and Hum Retroviruses* 2007, 23(9):1105-13. [Lien PubMed](#)

Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. *Antiviral Therapy* 2007, 12(1):31-39. [Lien PubMed](#)

Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figueredo S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG, for the ANRS VAC16 Study Group . Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial. *PLoS One* 2007, 2(8):e725. [Lien PubMed](#)

2006

Toneatti C, Saïdi Y, Meiffrédy V, Tangre P, Harel M, Eliette V, Dormont J, Aboulker JP. Experience using MedDRA for global events coding in HIV clinical trials. *Contemporary Clinical Trials* 2006, 27:13-22. [Lien PubMed](#)

Lévy Y, Durier C, Lascaux A.S., Meiffrédy V, Gahéry-Ségard H, Goujard C, Rouzioux C, Resch M, ElHabib R, Beumont-Mauviel M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP. Sustained control of viremia following therapeutic immunization in chronically HIV-1 infected individuals. *AIDS* 2006, 20:405-13. [Lien PubMed](#)

Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet J-G, Pialoux G, Aboulker J-P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. *AIDS* 2006, 20:1039-1049. [Lien PubMed](#)

Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker JP, Autran B, Venet A, and the ANRS ELISpot standardization group. Evaluation of the interlaboratory concordance in quantification of HIV-specific T cells with a gamma interferon enzyme-linked immunospot assay. *Clin Vacc Immunol* 2006, 13:684-697. [Lien PubMed](#)

Yeni P, Cooper DA, Aboulker J-P, Babiker AG, Carey D, Darbyshire JH, Florida M, Girard P-M, Goodall RL, Hooker MH, Mijch A, Meiffrédy V, Salzberger B, Antunes F, Becker M, Boukli N, Brun-Vézinet F, Churchill D, Conway B, Chazallon C, de Wit S, Dusak B, Emery S, Flepp M, Gatell J, Hemmer R, Law M, Loveday C, Lundgren J, Manion D, Mulcahy F, Orani A, Pharo C, Ristola M, Sandstrom E, Schechter M, Schnittman S, Seligmann M, Staszewski S, Stek M, Verbiest W, Weber J, Withnall R. Virological and immunological outcomes at three years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. *The Lancet* 2006, 368:287-298. [Lien PubMed](#)

Flandre P, Pinçon C, Aboulker J-P, Brun-Vézinet F, Pialoux G, Raffi F, and Descamps D. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. *HIV Clin Trials* 2006, 7:116-124. [Lien PubMed](#)

Marcelin G, Chazallon C, Gérard L, Saïdi Y, Aboulker JP, Girard PM, Calvez V, Piketty C. External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients. *JAIDS* 2006, 42:127-28. [Lien PubMed](#)

[PubMed](#)

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel FO, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. *Ant Ther* 2006, 11:213-21. [Lien PubMed](#)

Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker A, Aboulker J-P, Lyall H, Bachelier L, Walker AS, Debré M, Rosso R, Burger D, Della Negra M, Dunn DT, and Giaquinto C, on behalf of the Paediatric European Network for the Treatment of AIDS (PENTA). A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1- infected children: the PERA (PENTA 8) Trial. *Antiviral Therapy* 2006, 11:857-67. [Lien PubMed](#)

2005

Levy Y, Gahery-Segard H, Durier C, Lascaux A.S., Goujard C, Meiffrédy V, Rouzioux C, Habib R, Beumont-Mauviel M, Guillet JG, Delfraissy JF, Aboulker JP, and the ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. *AIDS* 2005, 19:279-86. [Lien PubMed](#)

Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gerard L, Yeni P, Aboulker JP, for the Agence Nationale de Recherches sur le SIDA 081 Study Group. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomised comparison of 2 regimens, including 3 drugs from 2 or 3 classes. *J Acquir Immune Defic Syndr* 2005, 38:268-76. [Lien PubMed](#)

Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial : (Novavir ANRS 073). *J Clin Virol* 2005, 33:99-103. [Lien PubMed](#)

Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentré F, Peytavin G, Gérard L, Becquemont L, Aboulker JP, for the ANRS 081 Study Group. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. *AIDS* 2005, 19 :2127-31. [Lien PubMed](#)

Hoën B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C for the Primstop study group. Structured Treatment Interruptions in Primary HIV-1 Infection: the ANRS 100 PRIMSTOP Trial *J AIDS* 2005, 40:307-16. [Lien PubMed](#)

Dunn DT, Gibb DM, Duong T, Babiker AG, Aboulker JP, Bulterys M, Cortina-Borja M, Gabiano C, Galli L, Giaquinto C, Harris DR, Hughes M, McKinney R, Moye J, Newell ML, Pahwa S, Palumbo P, Rudin C, Sharland M, Shearer W, Thompson B, Tookey P. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. *Lancet* 2005, 366:1868-74. [Lien PubMed](#)

Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. *Antimicrob Ag Chem* 2005, 49:525-35. [Lien PubMed](#)

2004

Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saïdi Y, Walker AS; Paediatric European Network for Treatment of AIDS (PENTA). Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. *AIDS* 2004, 18:237-45. [Lien PubMed](#)

Piketty C, Gérard L, Chazallon C, Calvez V, Clavel F, Taburet AM, Girard PM, Aboulker JP and the ANRS 107 Puzzle 2 study group. Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures. *AIDS* 2004, 18:1469-71. [Lien PubMed](#)

Taburet AM, Piketty C, Chazallon C, Vincent, I, Gérard L, Calvez V, Clavel F, Aboulker JP, Girard PM, and the ANRS protocol 107 Puzzle 2 investigators. Interactions between atazanavir-ritonavir and tenofovir in heavily

pretreated human immunodeficiency virus-infected patients. Antimicrobial agents and Chemotherapy 2004, 48:2091-96. [Lien PubMed](#)

2003

Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP and the ANRS 079 study group. Effects of Interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomised controlled trial. AIDS 2003, 17 : 343-351. [Lien PubMed](#)

Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E. Pharmacokinetics of Nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003, 22 : 48-55. [Lien PubMed](#)

Diagbouga S, Chazallon C, Kazatchkine M, Van de Perre P, Inwoley A, M'Boup S, Prince David M, Ténin Aoua Thiéro, Soudré R, Aboulker JP, Weiss L. Successful implementation of a low cost method for enumerating CD4+ T lymphocytes in resource-limited settings (ANRS 12-26 study). AIDS 2003, 17: 2201-2208. [Lien PubMed](#)

Lan NT, Recordon-Pinson P, Hung PV, Uyen NT, Lien TT, Tien HT, Garrigue I, Schrive MH, Pellegrin I, Lafon ME, Aboulker JP, Barre-Sinoussi F, Fleury HJ. HIV-1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam) : ANRS 1257 study . Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses 2003, 19:925-28. [Lien PubMed](#)

2002

Flandre Ph, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Pialoux G, Aboulker JP, Brun-Vézinet F. Final analysis of the Trilège induction-maintenance trial: results at 18 months. AIDS 2002, 16 : 561-568. [Lien PubMed](#)

Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. The Lancet 2002, 359 : 733-740. [Lien PubMed](#)

Flandre P, Durier C, Descamps D, Launay O, Joly V. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: Statistical analysis and potential biases. J Acquir Immune Defic Syndr 2002, 30 : 59-64. [Lien PubMed](#)

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi R. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antiviral Therapy 2002, 7 : 113-121. [Lien PubMed](#)

Joly V, Flandre P, Meiffredy V, Brun-Vézinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P for the Novavir Study Group. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (Novavir Trial). Antimicrob Agents Chemother 2002, 46 : 1906-1913. [Lien PubMed](#)

Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Patrick Yeni P. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. Clin Infect Dis 2002, 35 : 1096-1105. [Lien PubMed](#)

Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL, for the International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomised trial. JAMA 2002, 288 : 189-198. [Lien PubMed](#)

Descamps D, Flandre P, Joly V, Meiffredy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F on behalf of the NOVAVIR (ANRS 073) Study Group. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. JAIDS 2002, 31 : 464-471. [Lien PubMed](#)

Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L and Sullivan JL for the Pediatric AIDS Clinical Trials Group Protocol 316 Team. Development of resistance mutations in women on standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal HIV-1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. JFNDIS 2002;186:181-188. [Lien PubMed](#)

Saman M, Kruey LS, Glaziou P, Rekacewicz C, Leng C, Delfraissy JF. Feasibility of antenatal and late HIV testing in pregnant women, in Phnom Penh Cambodia: preliminary results of the PERIKAM/ANRS1205 study. AIDS 2002;16:950-951. [Lien PubMed](#)

Joly V, Flandre P, Meiffrédy V, Leturque N, Harel M, Aboulker JP, Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454. [Lien PubMed](#)

2001

Paediatric European Network for Treatment of AIDS (PENTA). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001, 84 : 230-236. [Lien PubMed](#)

Toneatti C, Debled P, Cassard S. Financial contracts between sponsors and investigators. Applied Clinical Trials avril 2001 : 64-68.

Pialoux G, Gahéry-Ségard H, Sermet S, Poncelet H, Fournier S, Gérard L, Tartar A, Gras-Masse H, Levy JP, Guillet JG. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001, 15 : 1239-49. [Lien PubMed](#)

Scott-Algara D, Aboulker JP, Durier C, Badell E, Marcellin F, Prud'homme M, Jouanne C, Meiffredy V, Brun-Vézinet F, Pialoux G, Raffi F. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART. Clin Exp Immunol 2001, 126 : 295-303. [Lien PubMed](#)

Delta Co-ordinating Committee of the Delta Trial. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy. HIV Med 2001, 2 : 181-188. [Lien PubMed](#)

Abgrall S, Charreau I, Joly V, Bloch J, Reynes J. Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues. Eur J Clin Microbiol Infect Dis 2001, 20 : 346-349. [Lien PubMed](#)

Gougeon ML, Rouzioux C, Liberman I, Burgard M, Taoufik Y, Viard JP, Bouchenafa K, Capitant C, Delfraissy JF. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS 2001, 15 : 1729-1731. [Lien PubMed](#)

Rabaud CH, Charreau I, Izard S, Raffi F, Meiffredy V, Leport C, Guillemin F, Yeni P, Aboulker JP. Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent disease progression. Scand J Infect Dis 2001, 33 : 759-764. [Lien PubMed](#)

2000

Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Mechanisms of Virologic Failure in previously Untreated HIV-infected Patients From a Trial of induction-Maintenance Therapy. Jama 2000, vol 283 : 205-211. [Lien PubMed](#)

Aboulker JP. Essai Clinique : les racines de la méthode. La Revue du Praticien 2000, 50 : 829-832. [Lien PubMed](#)

1999

Flandre Ph, Saïdi Y. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med. 1999, 18 : 107-9.

O'Quigley J, Flandre Ph, Reiner E. Large sample theory for Schemper's measures of explained variation in the cox regression model. *J. R. Statist. Soc. D*, 42 : 53-62.

Flandre Ph on behalf of the Delta Coordinating Committee. Patients with HIV-1 RNA below 1000 copies after 48 weeks on treatment (AZT+ddl or AZT+ddC) : baseline characteristics and pronostic. *AIDS* 1999, 13 : 430-31. [Lien PubMed](#)

Delta Coordinating Committee and Virology Group. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial : an extended virology study. *AIDS* 1999, 13 : 57-65. [Lien PubMed](#)

Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. *AIDS* 1999, 13 : 565-573. [Lien PubMed](#)

The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission : a randomised clinical trial. *The Lancet* 1999, 1035-39. [Lien PubMed](#)

Aboulker JP, Dormont J. Les inhibiteurs nucléosidiques de la transcriptase inverse : les pionniers de la thérapie anti-VIH.. *Virologie mars* 1999, vol.3.

Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boumsell L, Gomard E, Rabian C, Weiss L, Guillet JG, Delfraissy JF, Aboulker JP, Seligmann M, and the ANRS 048 study group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection : a randomised controlled trial. *The Lancet* 1999, 353 : 1923-29. [Lien PubMed](#)

Raffi F, Franck J, Pelloux H, Derouin F, Reliquet V, Ambroise-thomas P, Aboulker JP, Leport C, Dumon H. Specific Anti-Toxoplasmic IgG Antibody Immunoblot Profiles in Patients with AIDS-Associated Toxoplasma Encephalitis. *Diagn Microbiol Infect Dis* 1999, 34 : 51-56. [Lien PubMed](#)

Salmon-Ceron D, Fillet AM, Aboulker JP, Gerard L, Houhou N, Carrier I, Ostinelli J, Vildé JL, Brun-Vezinet F, Leport C, and the ANRS 023. Effect of a 14-Days Course of Foscarnet on Cytomegalovirus (CMV) blood Markers in a Randomized Study of Human Immunodeficiency virus infected Patients with Persistent CMV Viremia. *Clinical Infectious Diseases* 1999, 28 : 901-5. [Lien PubMed](#)

Masquelier B, Descamps D, Carrière I, Ferchal F, Collin G, Denayrolles M, Ruffault A, Chanzy B, Izopet J, Buffet-Janvresse C, Schmitt MP, Race E, Fleury HJA, Aboulker JP, Yeni P, Brun-Vezinet F. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study. *Antiviral Therapy* 1999, 4 : 69-77. [Lien PubMed](#)

Zou WP, Foussat A, Capitant C, Durand-Gasselini I, Bouchet L, Galanaud P, Levy Y, Emilie D. Acute activation of CD8 (+) T-Lymphocytes in Interleukine-2 – Treated HIV-Infected Patients. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 1999, 22 (1) : 31-38. [Lien PubMed](#)

Zou W, Foussat A, Capitant C, Durand-Gasselini I, Bouchet L, Galanaud P, Levy Y, Emilie D. Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. *AIDS* 1999, 13(4) : 455-463.

Aboulker JP. Drug-resistant Genotyping in HIV-1 Therapy. *The Lancet*, 1999, 354 (: 1120) (Lettre). [Lien PubMed](#)

1998

Newell ML, Parazzini F, Mandelbrot L, Peckam C, Semprini A, Bazin B, Darbyshire J, Sanchez E, Pardi E. A randomised trial of mode of delivery in women infected with the human immunodeficiency virus. *British Journal of Obstetrics and Gynaecology* 1998, 105 : 281-285. [Lien PubMed](#)

Flandre Ph. Analysing survival in the presence of an auxiliary variable. *Stat. Med.* 1998, 17 : 239-241. [Lien PubMed](#)

Piketty C, Castiel Ph, Belec L, Batische D, Si Mohamed A, Gilquin J, Gonzales-Canali G, Jayle D, Karmochkine M, Weiss L, Aboulker JP and Kazatchkine M. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. *AIDS* 1998, 12 : 745-750. [Lien PubMed](#)

Paediatric European Network for Treatment of Aids (Penta). HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. AIDS 1998, 12 : F1-F8. [Lien PubMed](#)

Joint Concorde and Opal Coordinating Committee. Long term follow-up of randomized Trials of immediate versus deferred Zidovudine in symptom-free HIV infections. AIDS 1998, 12 :1259-65. [Lien PubMed](#)

Bloch J, Chavance M. A mixed model for repeated Dilution assays. Biometrics June 1998, Vol 54 : 482-92. [Lien PubMed](#)

Pialoux G, Raffi F, Brun-Vézinet F, Meiffrédy V, Flandre Ph, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. For the Trilège (ANRS 072) Study Team. A randomized trial of three maintenance regimens given after three months of induction therapy with Zidovudine, Lamivudine, and Indinavir in previously untreated HIV-1 infected patients. New Eng. J Med. 1998, 339 : 1269-76. [Lien PubMed](#)

Chêne G, Morlat Ph, Leport C, Hafner R, Dequae L, Charreau I, Aboulker JP, Luft B, Aubertin J, Vildé JL, Salamon R, and members of the ANRS 005/ACTG 154 Trial Group. Intention-to-Treat vs. On-Treatment Analyses of Clinical Trial Data : Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-infected Patients. Controlled Clinical Trials 1998, 19 : 233-48. [Lien PubMed](#)

Albert JA, Ioannidis J, Reichelderfer P, Connay B, Coombs RW, Crane L, Demasi R, Dixon DO, Flandre Ph, Hugues MD, Kalish L, Larntz K, Lyn D, Marschner IC, Munoz A, Murray J, Neaton J, Pettinelli C, Rida W, Taylor Jeremy MG, Welles I. Statistical issues for HIV surrogate endpoints : point/counterpoint. Stat. Med. 1998, 17 : 435-62. [Lien PubMed](#)

Paediatric European Network for Treatment of AIDS. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 1998, 12 : F151-F160. [Lien PubMed](#)

Bourezane Y, Salard D, Hoen B, Vandell S, Drobacheff C, Laurent R. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome associated with nevirapine therapy. Clin. Infect. Dis, 1998, 27 : 1321-2. [Lien PubMed](#)

1997

Raffi F, Aboulker JP, Michelet C, Reliquet V, Pelloux H, Huart A, Poizot-Martin I, Morlat Ph, Dupas B, Mussini JM, Leport C, and the Bio-Toxo study group. A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. AIDS 1997, 11 : 177-184. [Lien PubMed](#)

Coulaud JP, Gougeon ML, Gomard E, Brun-Vézinet F, Lebon P, Aboulker JP, Bizzini B, Zagury D. A placebo controlled clinical phase I trial with combined anti-HIV1 and anti-alpha interferon immunization. AIDS 1997, 11 : 937-8. [Lien PubMed](#)

Pelloux H, Dupouy-Camet J, Derouin F, Aboulker JP, Raffi F, and the Bio-Toxo Study Group. A multicentre prospective study for the polymerase chain reaction detection of Toxoplasma gondii DNA in blood samples from 186 AIDS patients with suspected toxoplasmic encephalitis. AIDS 1997, vol 11 : 1888-9. [Lien PubMed](#)

Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzysanowski C, Nunn A, Schuurman R, Seigneurin J-M, Tamalet C, Tedder R, Weber J, Weverling G-J, the National Virology Groups, and the Delta Virology Working Group and Coordinating Committee. HIV-1 viral load, phenotype, and resistance in a subset of drug-naïve participants from the Delta trial. The Lancet 1997, 350 : 983-990. [Lien PubMed](#)

Gérard L, Leport C, Flandre P, Hounou N, Salmon-Ceron D, Pépin JM, Mandet C, Brun-Vezinet F, Vildé JL. Cytomegalovirus (CMV) viremia and the CD4 + Lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 1997, 24 : 836-40. [Lien PubMed](#)

1996

Aboulker JP. The place of the protease inhibitors in antiretroviral combination therapy. Current Opinion in Infectious Disease. Rapid Science Publishers 1996, 9 : 19-22.

Dormont J, Brun-Vézinet F, Yeni P, Aboulker JP. Les antirétroviraux. Médecine Thérapeutique avril 1996, vol. 2 : hors série.

Joly V, Aubry P, Ndayiragide A, Carrière I, Kawa E, Mlika-Cabanne N, Aboulker JP, Coulaud JP, Larouze B, Yeni P. Randomised comparison of fungizone dissolved in glucose intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clinical Infectious Diseases 1996, 23 : 556-562. [Lien PubMed](#)

Delta Coordinating Committee. Delta : A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. The Lancet 1996, 348 : 283-291. [Lien PubMed](#)

Alpha International Coordinating Committee. The Alpha trial : European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV Disease. AIDS 1996, 10 : 867-80. [Lien PubMed](#)

Aboulker JP. Surrogate Markers in AIDS Clinical Trials. Proceedings of the International Falk Workshop, Basel, Switzerland, october 23-24, 1995. Kluwer Academic Publishers, 1996.

Flandre Ph. On the use of auxiliary data to estimate the survival function and its variance : An application to AIDS. J. Clin. Epidemiol. 1996, 49 : 899-905. [Lien PubMed](#)

1995

Salmon-Ceron D, Fontbonne A, Saba J, May T, Raffi F, Chidiac C, Patey O, Aboulker JP, Schwartz D, Vildé JL, and the Study Group. Lower survival in AIDS patients receiving Dapsone compared with aerosolized Pentamidine of secondary prophylaxis of pneumocystis carinii pneumonia. The Journal of Infectious Diseases, 1995, 172 : 656-664. [Lien PubMed](#)

Gibb DM, Darbyshire JH, Debré M, Giaquinto C, Aboulker JP, Martinez M, Tudor-Williams G, for Penta. Treatment of children with HIV infection. The Lancet 1995, 345 : 1115. [Lien PubMed](#)

1994

Concorde Coordinating Committee. Concorde : MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343-387. [Lien PubMed](#)

Connor EM, Sperling RS, Gelber R, et AL. Reduction of Maternal infant transmission of human immunodeficiency virus type 1 with Zidovudine treatment. N England J Med 1994 ; 331 : 1173-80. [Lien PubMed](#)

Oksenhendler E, Charreau I, Tournerie C, Azihary M, Carbon C, and Aboulker JP. Toxoplasma gondii infection in advanced HIV infection AIDS 1994, 8 : 483-87. [Lien PubMed](#)

Dormont J, Aboulker JP. Les traitements antirétroviraux dans l'infection par le virus de l'immunodéficience humaine (VIH). Rev Prat (Paris) 1994, 44, 12, 1635-1642. [Lien PubMed](#)

1993

Aboulker JP, Swart AM. Preliminary analysis of the Concorde Trial. Lancet 1993, 341 : 899-90. [Lien PubMed](#)

1992

Aboulker JP, Autran B, Beldjord K, Touraine F, Debré P. Consistency of routine CD4+, CD8+ peripheral blood lymphocyte measurements. Journal of Immunological Methods 1992, 154 : 155-61. [Lien PubMed](#)

1989

Article paru dans la presse :

m/s n°3, vol 5, mars 89 :

[L'évaluation de traitement et autres moyens de lutte contre le SIDA par le Pr Daniel SCHWARTZ et le Dr Jean-Pierre ABOULKER](#)